Generics beat Amgen's Enbrel in RA showdown; Immune Design teams up to test combo cancer approach;

@FierceBiotech: Firm tries startup's tech tricks for clinical trial recruitment. Article | Follow @FierceBiotech

 @JohnCFierce: Report stirs debate over the true impact of the genomics revolution. More | Follow @JohnCFierce

@RyanMFierce: Add this AMG386 data to VTec results, and Amgen is 2 for 2 with Ph3 oncology programs this year. Devil's in the details, though. | Follow @RyanMFierce

 @EmilyMFierce: At a genomics briefing on the Hill. NIH Director Francis Collins says 25,000 jobs in biomedical research will be lost due to sequestration. | Follow @EmilyMFierce

> In a potential threat to one of Amgen's ($AMGN) big drug franchises, a new study says a cocktail of generic treatments proved better than Enbrel in treating rheumatoid arthritis. Story (sub. req.)

> The Cancer Research Institute, the Ludwig Institute for Cancer Research and Immune Design have teamed up to mount clinical trials to test novel combinations of immunotherapies, including two investigational drugs from Immune Design's pipeline. "The collaboration with Immune Design marks the third in a series of CRI and Ludwig partnerships with industry designed to facilitate the investigation of next generation combination immunotherapies," said Adam Kolom, managing director of CRI's non-profit venture fund. No financial terms were disclosed. Release

> The Boston Business Journal notes that Flagship Ventures has enjoyed a pair of successful biotech IPOs--for Tetraphase and Receptos--this year, with a third for Agios waiting in the wings. Story

> The FDA is pondering the possibility of starting a trial to determine if diabetes blockbusters like Merck's ($MRK) Januvia and Bristol-Myers Squibb's ($BMY) Byetta can raise the risk of cancer. Story

Medical Device News

@FierceMedDev: Study: Balloon implant reduced rectal damage during prostate cancer treatment. Item | Follow @FierceMedDev

@DamianFierce: Diagnostics companies gouged Medicare by almost $1B in 2011, according to the feds. Report | Follow @DamianFierce

@MarkHFierce: We need your FMD Fierce 15 nominations. Submit them courtesy of this handy link: Nomination form | Follow @MarkHFierce

> RTI will drop $130M on Pioneer with eye on bone implants. News

> Mystery solved? Research blames ruptured plaque for stent related blood clots. More

> St. Jude wins FDA nods for low-friction cardiac devices. Article

Pharma News

@FiercePharma: Novartis acknowledges investigation of allegations of sales scheme in India, some employees have been fired. Story | Follow @FiercePharma

@EricPFierce: ANSM in France says no problems found in Teva packaging of Furosemide product tampering a possibility. More | Follow @EricPFierce

@CarlyHFierce: Teva's at-risk launch of generic Protonix a bit riskier than it thought. Teva & Sun to pay $2.15B to Pfizer. Article | Follow @CarlyHFierce

> Cheaper generic combo found as effective in RA as blockbuster Enbrel. News

> Confab reviews safety of diabetes drugs like Merck's Januvia, Novo's Victoza. Article

> France finds no problems at Teva plant. More

Drug Delivery News

@MichaelGFierce: Pearl's porous particle platform nets $1.15B AstraZeneca buyout. More | Follow @MichaelGFierce

> Ocular draws funding from Baxter to support hydrogel delivery platform. Item

> Origami inspires 3-D folded structures for drug delivery. Article

> New research further reveals nano-gold's delivery potential, safety risk. Story

Biomarkers News

> Heart experts link biomarkers with high risk of 'silent strokes.' Report

> Stunted telomeres might flag breast cancer risk. Article

> Genetic biomarker could help scientists select cell lines for stem cell studies. More

> Cancer Research UK, Abcodia to develop blood Dx attuned to early-stage cancers. Item

> Biomarker aids in gestational diabetes risk prediction. Story

And Finally… An analysis of adult survivors of childhood cancer found a high prevalence of chronic diseases in the group. And the risk clearly grows with age. Release

 

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.